Article

AAO 2019 Retina Street Team: John T. Thompson, MD

Author(s):

AAO 2019 Retina Street Team

John T. Thompson, MD, discusses retinal relativity and reimbursement roulette during Day 2 of the 2019 American Academy of Ophthalmology's annual meeting.

Read and watch more AAO 2019 Retina Street Team content.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
PYC to finalize registrational study for RP11 after positive FDA feedback
June 28th 2025

PYC to finalize registrational study for RP11 after positive FDA feedback

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

Breye Therapeutics reports completion of phase 1b for oral NPDR therapy
June 25th 2025

Breye Therapeutics reports completion of phase 1b for oral NPDR therapy

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001
June 25th 2025

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001

© 2025 MJH Life Sciences

All rights reserved.